Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $12.00, for a total transaction of $19,620.00. Following the completion of the transaction, the insider owned 8,617 shares of the company’s stock, valued at $103,404. This trade represents a 15.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total value of $19,947.00.
• On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $117,720.00.

4D Molecular Therapeutics Stock Performance

FDMT opened at $14.72 on Wednesday. The business has a 50 day moving average price of $11.17 and a two-hundred day moving average price of $9.97. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. The company has a market capitalization of $769.56 million, a price-to-earnings ratio of -5.60 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a 1-year low of $5.97 and a 1-year high of $15.04.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The firm had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. Research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of FDMT. Dynamic Technology Lab Private Ltd purchased a new stake in 4D Molecular Therapeutics during the first quarter valued at about $39,000. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter valued at approximately $41,000. AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $46,000. Daiwa Securities Group Inc. lifted its position in shares of 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after acquiring an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new position in 4D Molecular Therapeutics in the 2nd quarter worth approximately $48,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

More 4D Molecular Therapeutics News

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $36 price target, implying substantial upside from recent trading levels. The firm modestly improved its FY2027 EPS forecast to a loss of $4.34 per share from $4.40, while projecting narrowing losses through FY2030. HC Wainwright analyst estimates
• Positive Sentiment: Other analysts remain constructive: Goldman Sachs reiterated a Buy rating with a $32 target, while the broader analyst consensus is Moderate Buy with an average price target of $29.62. 4D Molecular Therapeutics reaches 12-month high
• Positive Sentiment: FDMT recently reached a new 12-month high, trading well above its 50-day and 200-day moving averages. The stock’s elevated volume and momentum may be attracting additional interest, although its high beta indicates significant volatility. 4D Molecular Therapeutics reaches 12-month high
• Neutral Sentiment: Institutional ownership is reported at 99.27%, with new positions from Bank of America, Man Group, Jupiter Topco and other investors. This signals strong institutional interest, though the reported purchase figures may include data-quality anomalies. Institutional ownership and insider trading
• Negative Sentiment: HC Wainwright reduced its FY2028, FY2029 and FY2030 loss estimates slightly, indicating that FDMT is expected to remain unprofitable for several years. The company also recently reported a quarterly loss of $1.04 per share, missing estimates, despite revenue exceeding expectations.
• Negative Sentiment: Insider Scott Bizily sold shares in multiple transactions totaling roughly $39,567 during August and has reduced his direct holdings by 15.95%. While relatively small, the sales could temper investor sentiment. FDMT insider stock sales

Analyst Ratings Changes

Several equities research analysts have commented on FDMT shares. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $29.62.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.